In detail, a signature of eight genes, namely, IL6, CXCL10, CCL20, CXCL2, CXCL8, CXCL1, ICAM1, and CXCL3, emerged and highlighted ccRCC patients with adverse clinical outcomes expressing elevated levels of at least one of these mRNAs (Supplementary Figure S6). This evidence concerns the gene CXCL10 and nonpapillary renal cell carcinoma.